Surgical resection of primary tumor in the extremities improves survival for metastatic soft-tissue sarcoma patients: A population-based study of the seer database
-
M. Matsuoka [1] ; T. Onodera [1] ; I. Yokota [1] ; K. Iwasaki [1] ; S. Matsubara [1] ; R. Hishimura [1] ; E. Kondo [1] ; N. Iwasaki [1]
-
[1] Hokkaido University
Hokkaido University
Chūō-ku, Japón
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 12 (Diciembre), 2021, págs. 2474-2481
- Idioma: inglés
- Enlaces
-
Resumen
Purpose The objectives of this study were to clarify whether resection of primary tumor in the extremities for patients with metastatic soft-tissue sarcoma (STS) improves survival, and to clarify patient groups for whom primary tumor resection should be considered.
Methods/patients Using the surveillance, epidemiology, and end results database, we identified 1453 patients with metastatic STS of the extremities at initial presentation between 1983 and 2016. Of these 1453 patients, 898 patients underwent primary tumor resection (Surgery group), and 555 patients did not (No-surgery group).
Results After adjusting for patient background by propensity score matching, a total of 804 patients were included for analysis. Patients in the Surgery group showed improved survival (cancer-specific survival (CSS) hazard ratio (HR) = 0.59, 95% confidence interval (CI) 0.50–0.71 overall survival rate (OS) HR = 0.60, 95% CI 0.51–0.70). In subclass analysis, patients with high-grade STS, undifferentiated pleomorphic sarcoma, leiomyosarcoma, or synovial sarcoma showed improved survival in the Surgery group (high grade—CSS HR = 0.57, 95% CI 0.45–0.72, OS HR = 0.58, 95% CI 0.48–0.71; undifferentiated pleomorphic sarcoma—CSS HR = 0.60, 95% CI 0.42–0.84, OS HR = 0.61, 95% CI 0.46–0.82; leiomyosarcoma—CSS HR = 0.50, 95% CI 0.33–0.75, OS HR = 0.50, 95% CI 0.35–0.72; synovial sarcoma—CSS HR = 0.46, 95% CI 0.31–0.68, OS HR = 0.43, 95% CI 0.30–0.62).
Conclusions Our results indicated that primary tumor resection in metastatic STS exerts positive impacts on survival. Further clinical research is needed to confirm these results.
